AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEUROSCIENTIFIC BIOPHARMACEU

0.130

0.000

Volume:118.24K

Turnover:15.37K

Market Cap:43.23M

PE:-10.32

High:0.130

Open:0.130

Low:0.130

Close:0.130

52wk High:0.260

52wk Low:0.034

Shares:332.58M

Float Shares:243.14M

Volume Ratio:2.15

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.013

EPS(LYR):-0.013

ROE:-16.65%

ROA:-11.21%

PB:2.57

PE(LYR):-10.33

Loading ...

Overview Company News Filings

BUZZ-Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results

BRIEF-Neuroscientific Biopharmaceuticals Requests Trading Halt

NeuroScientific Biopharmaceuticals - Requests Halt Pending Special Access Program Results

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Ltd-Investor Webinar Update

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Ltd-Clinical & Scientific Advisory Board Appointed

THOMSON REUTERS

NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator

MT Newswires Live

NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%

MT Newswires Live

NeuroScientific Biopharmaceuticals Begins Transfer of Manufacturing Process for Mesenchymal Stromal Cell to Q-Gen Cell Therapeutics; Shares Rise 4%

MT Newswires Live

NeuroScientific Biopharmaceuticals Appoints CEO; Shares Up 9%

MT Newswires Live

BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO

NeuroScientific Biopharmaceuticals Ltd - Appoints Nathan Smith as CEO

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Appoints Chief Medical Officer; Shares Up 4%

MT Newswires Live

NeuroScientific Biopharmaceuticals Ltd-DR Catherine Cole Appointed as Chief Medical Officer

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NSB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","market":"AU","secType":"STK","nameCN":"NEUROSCIENTIFIC BIOPHARMACEU","latestPrice":0.13,"timestamp":1770959520000,"preClose":0.13,"halted":0,"volume":118243,"delay":0,"changeRate":0,"nameEN":"NEUROSCIENTIFIC BIOPHARMACEU","floatShares":243142540,"shares":332575706,"eps":-0.0126,"marketStatus":"Market Closed","change":0,"latestTime":"02-13 16:12:00 AEDT","open":0.13,"high":0.13,"low":0.13,"amount":15372,"amplitude":0,"askPrice":0.13,"askSize":3271,"bidPrice":0.125,"bidSize":80095,"shortable":3,"etf":0,"ttmEps":-0.0126,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1771196400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.13,"openAndCloseTimeList":[[1770937200000,1770958800000]],"volumeRatio":2.145535,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","floatShares":243142540,"roa":"-11.21%","roe":"-16.65%","lyrEps":-0.012583,"volumeRatio":2.145535,"shares":332575706,"dividePrice":0,"high":0.13,"amplitude":0,"preClose":0.13,"low":0.13,"week52Low":0.034,"pbRate":"2.57","psRate":"260.33","week52High":0.26,"institutionHeld":0,"latestPrice":0.13,"committee":0.921527,"eps":-0.0126,"divideRate":0,"volume":118243,"delay":0,"ttmEps":-0.0126,"open":0.13,"prevYearClose":0.11,"prevWeekClose":0.13,"prevMonthClose":0.14,"prevQuarterClose":0.11,"fiveDayClose":0.13,"twentyDayClose":0.15,"sixtyDayClose":0.125},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2603757667","title":"BUZZ-Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results","url":"https://stock-news.laohu8.com/highlight/detail?id=2603757667","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603757667?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:47","pubTimestamp":1768272464,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's NeuroScientific Biopharmaceuticals surges on positive clinical results** Shares of NeuroScientific Biopharmaceuticals NSB.AX rise as much as 52.2% to A$0.175, their highest level since September 24, 2025** Biopharmaceutical co heading for best day since April 2025, if current gains hold** Co announces successful clinical results from fistulising crohn's disease patients treated with its StemSmart mesenchymal stem cell therapy** Says three of four patients demonstrated successful clinical response when treated with StemSmart** About 4.3 mln shares change hands, 25.7x the 30-day average, in the busiest day since July 24, 2025** Stock more than tripled in value last year   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nL6N3YE06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSB.AU","BK7067"],"gpt_icon":0},{"id":"2602315770","title":"BRIEF-Neuroscientific Biopharmaceuticals Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2602315770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602315770?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:28","pubTimestamp":1767911336,"startTime":"0","endTime":"0","summary":"BRIEF-Neuroscientific Biopharmaceuticals Requests Trading Halt Jan 9 (Reuters) - NeuroScientific Biopharmaceuticals Ltd NSB.AX:REQUESTS HALT PENDING SPECIAL ACCESS PROGRAM RESULTSFurther company coverage: NSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2602731577","title":"NeuroScientific Biopharmaceuticals - Requests Halt Pending Special Access Program Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2602731577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602731577?lang=en_us&edition=fundamental","pubTime":"2026-01-09 06:28","pubTimestamp":1767911308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y90GM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2582313277","title":"NeuroScientific Biopharmaceuticals Ltd-Investor Webinar Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2582313277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582313277?lang=en_us&edition=fundamental","pubTime":"2025-11-12 07:00","pubTimestamp":1762902046,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251111:nTUEP52KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2581831850","title":"NeuroScientific Biopharmaceuticals Ltd-Clinical & Scientific Advisory Board Appointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2581831850","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581831850?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:28","pubTimestamp":1762381700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nTUE5PS0DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2573392439","title":"NeuroScientific Says StemSmart Therapy Treatment for Fistulizing Crohn's Disease Patients Approved by Australian Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=2573392439","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573392439?lang=en_us&edition=fundamental","pubTime":"2025-10-07 12:44","pubTimestamp":1759812275,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  said the first three patients in the first group with fistulizing Crohn's disease were approved by Australia's Therapeutic Goods Administration for treatment with the patented StemSmart mesenchymal stromal cell  technology, according to a Tuesday Australian bourse filing.Approved patients in the first group will progress towards treatment with StemSmart mesenchymal stem cells in line with its Special Access program, and the outcomes of the program are planned to support the development of a future phase 2 clinical trial in refractory Crohn's disease, planned for 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","XKO.AU","NSB.AU","MSC","XAO.AU","BK4150","XJO.AU","BK4575"],"gpt_icon":0},{"id":"2562799788","title":"NeuroScientific Says Review of Biotechnology Firm's Data Shows 'Promising' Results for StemSmart Therapy in Renal Transplants, Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562799788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562799788?lang=en_us&edition=fundamental","pubTime":"2025-08-27 13:16","pubTimestamp":1756271798,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  said that a review of historical studies, data, findings, and publications following the acquisition of Isopogen WA found that StemSmart mesenchymal stromal cell  therapy showed \"promising\" results in two early studies in renal transplantation, according to a Wednesday Australian bourse filing.Isopogen WA is the holder of StemSmart, a patented stem cell technology.The studies support further clinical development and the potential of StemSmart MSC in both preventing and treating graft failure and rejection, the firm noted.A case series of 10 adult patients with treatment-refractory acute renal rejection following kidney transplants were treated with StemSmart MSC as a salvage and adjunctive therapy. Eight out of 10 patients retained their kidney following the infusion.A second study undertaken in 12 adults undergoing deceased-donor renal transplantation showed that StemSmart MSC infusion was well tolerated and safe, and the results were \"encouraging\" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4575","BK4150","BK7067","NSB.AU","MSC"],"gpt_icon":0},{"id":"2555008711","title":"NeuroScientific Biopharmaceuticals Begins Transfer of Manufacturing Process for Mesenchymal Stromal Cell to Q-Gen Cell Therapeutics; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008711","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555008711?lang=en_us&edition=fundamental","pubTime":"2025-07-31 13:23","pubTimestamp":1753939406,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) began the transfer of its patented manufacturing process for its mesenchymal stromal cells from cell and tissue therapy at the Royal Perth Hospital in West","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","XAO.AU","GEN","XJO.AU","XKO.AU","BK4588","BK4097","BK4585","BK4139","LU2286300806.USD","LENZ","NSB.AU","BK7067"],"gpt_icon":0},{"id":"2554204728","title":"NeuroScientific Biopharmaceuticals Appoints CEO; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554204728","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554204728?lang=en_us&edition=fundamental","pubTime":"2025-07-28 13:38","pubTimestamp":1753681139,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) appointed Nathan Smith as chief executive officer, effective Monday, July 28, according to a same-day filing with the Australian bourse.The company's shares were up 9% in recent Monday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","NSB.AU","XAO.AU","XKO.AU","XJO.AU"],"gpt_icon":0},{"id":"2554326744","title":"BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554326744","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554326744?lang=en_us&edition=fundamental","pubTime":"2025-07-28 09:48","pubTimestamp":1753667320,"startTime":"0","endTime":"0","summary":"BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEOJuly 28 (Reuters) - NeuroScientific Biopharmaceuticals Ltd NSB.AX:EXPERIENCED CELL THERAPY EXECUTIVE APPOINTED CEOAPPOINTS NATHAN SMITH AS CEOFurther company coverage: NSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE34YJVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2554963746","title":"NeuroScientific Biopharmaceuticals Ltd -  Appoints Nathan Smith as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554963746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554963746?lang=en_us&edition=fundamental","pubTime":"2025-07-28 07:19","pubTimestamp":1753658394,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250727:nTUE34YJVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSB.AU","BK7067"],"gpt_icon":0},{"id":"2554731471","title":"NeuroScientific Biopharmaceuticals Appoints Chief Medical Officer; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554731471","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554731471?lang=en_us&edition=fundamental","pubTime":"2025-07-25 08:58","pubTimestamp":1753405112,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Catherine Cole as chief medical officer, effective immediately, according to a Friday filing with the Australian bourse.The company's shares rose 4% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","BK7067","XAO.AU","NSB.AU"],"gpt_icon":0},{"id":"2554364767","title":"NeuroScientific Biopharmaceuticals Ltd-DR Catherine Cole Appointed as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2554364767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554364767?lang=en_us&edition=fundamental","pubTime":"2025-07-25 07:19","pubTimestamp":1753399192,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nTUE1XWFC1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}]}}